Bank of Nova Scotia Increases Bristol Myers Squibb Stake

The Canadian bank grew its holdings in the biopharmaceutical company by 41.9% in the third quarter.

Mar. 17, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Bank of Nova Scotia, a major Canadian financial institution, increased its stake in Bristol Myers Squibb Company by 41.9% during the third quarter of the year. The bank now owns 755,568 shares of the biopharmaceutical company, worth $34,076,000 at the end of the reporting period.

Why it matters

This investment move by Bank of Nova Scotia suggests the bank sees significant potential in Bristol Myers Squibb's future performance and growth prospects. As a major institutional investor, Bank of Nova Scotia's increased stake in the company could signal broader investor confidence in Bristol Myers Squibb's drug pipeline and business strategy.

The details

According to a filing with the Securities and Exchange Commission, Bank of Nova Scotia added 223,196 shares of Bristol Myers Squibb to its portfolio during the third quarter. This increased the bank's total holdings in the biopharmaceutical firm to 755,568 shares, worth $34,076,000 at the end of the reporting period.

  • Bank of Nova Scotia filed the disclosure about its increased Bristol Myers Squibb stake on March 17, 2026.
  • The bank grew its holdings in the third quarter of the year.

The players

Bank of Nova Scotia

A major Canadian financial institution and one of the largest banks in North America.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Bank of Nova Scotia's increased stake in Bristol Myers Squibb suggests the bank sees strong growth potential in the biopharmaceutical company's future. As a major institutional investor, the bank's investment move could signal broader confidence in Bristol Myers Squibb's drug pipeline and business strategy.